These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Therapy in Alzheimer disease]. Kovács T Orv Hetil; 2004 Apr; 145(17):925-8. PubMed ID: 15170971 [No Abstract] [Full Text] [Related]
23. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Harry RD; Zakzanis KK Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322 [TBL] [Abstract][Full Text] [Related]
24. Neuropsychiatric outcome for clinical trials. Robert P; Verhey FR; Aalten P; Cortes F; Byrne EJ J Nutr Health Aging; 2007; 11(4):345-7. PubMed ID: 17653496 [No Abstract] [Full Text] [Related]
27. [Alzheimer's disease: from brain lesions to new drugs]. Forette F; Hauw JJ Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689 [TBL] [Abstract][Full Text] [Related]
28. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Prasher VP Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527 [TBL] [Abstract][Full Text] [Related]
29. [The characteristics of Alzheimer's Disease Units in relation to neuropsychological tests]. Sorrentino GC; Caffari B; Vanacore N; Maggini M; Raschetti R Ann Ist Super Sanita; 2005; 41(1):63-8. PubMed ID: 16037652 [TBL] [Abstract][Full Text] [Related]
30. Clinical inquiries. Do patients at high risk of Alzheimer's disease benefit from early treatment? Holt J; Stiltner L; Wallace R; Raetz J J Fam Pract; 2009 Jun; 58(6):320-2. PubMed ID: 19508846 [TBL] [Abstract][Full Text] [Related]
31. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
33. [Management and therapy of Alzheimer's disease. Recommendations of a general practitioners' guideline]. Vollmar HC; Wilm S MMW Fortschr Med; 2009 Jun; 151(24):36-40; quiz 41. PubMed ID: 19645200 [No Abstract] [Full Text] [Related]
34. [Patient-relevant end points in Alzheimer's disease]. Frölich L Dtsch Med Wochenschr; 2006 May; 131(19 Suppl 1):S31-4. PubMed ID: 16688663 [TBL] [Abstract][Full Text] [Related]
35. [Dementias: mostly clinico-neuropsychological or mostly psychometric diagnosis?]. Spinnler H Ann Ist Super Sanita; 2005; 41(1):75-80. PubMed ID: 16037654 [TBL] [Abstract][Full Text] [Related]
36. [Diagnosis and therapy of Alzheimer's disease: what's important for the family doctor?]. Perneczky R; Kurz A MMW Fortschr Med; 2008 Dec; 150(49-50):42-5; quiz 46. PubMed ID: 19133370 [No Abstract] [Full Text] [Related]
37. [Is there a treatment for Alzheimer's disease?]. Joray S; Ghika J; von Gunten A; Büla C; Gold G; Assal F Rev Med Suisse; 2005 May; 1(18):1201-2, 1205-6, 1208. PubMed ID: 15977708 [TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease. Kennedy-Malone LM; Fletcher K Lippincotts Prim Care Pract; 1999; 3(2):163-8. PubMed ID: 10426059 [No Abstract] [Full Text] [Related]
39. Comments on research in the social sciences pertaining to Alzheimer's disease: a more humble approach. Post SG Aging Ment Health; 2001 May; 5 Suppl 1():S17-9. PubMed ID: 11513492 [TBL] [Abstract][Full Text] [Related]
40. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Chu LW; Yik PY; Mok W; Chung CP Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]